Evidence-Based Medicine
Copyright ©The Author(s) 2015.
World J Gastroenterol. Mar 14, 2015; 21(10): 3049-3054
Published online Mar 14, 2015. doi: 10.3748/wjg.v21.i10.3049
Table 1 Patients characteristics (n = 27)
Characteristicsmean ± SD or nRanges
Age (yr)58 ± 1029-72
Gender (Male/Female)24/3
Underlying liver disease
Alcohol8
Viral15
Other cirrhosis2
Non-cirrhotic liver2
AFP at transplant (ng/mL)199 ± 4760.9-1957
Milan at listingIn/out13/14
Neoadjuvant treatmentYes/no9/18
CHILDA/B/C9/10/8
OKUDAI/II/III7/15/5
CLIP0/1/2/3/41/7/9/6/4
Pathology
Number of nodules1/2/3/> 35/6/3/13
Size of largest lesion (cm)3.8 ± 2.21.5-1.5
DifferentiationLow/intermediate/high grade1/13/13
Microvascular invasionN/Y17/10
pTNM (7th)T1/T2/T3a/T3b/T44/16/5/1/1
pTNM (Yao)T1/T2/T3a/T3b/T4a/T4b0/8/5/1/12/1
Table 2 Univariate comparison of prognostic factors
Recurrence free survival
Global survival
HRP valueHRP value
TSUVmax/LSUVmax > 1.1514.40.015.620.04
TSUVmean/LSUVmean > 1.1514.40.015.620.04
Pretransplant treatment1.010.990.320.30
AFP0.990.471.000.52
Milan3.970.211.970.43
Portal vein thrombosis5.560.060.130.14
TNM (7th)1.930.361.930.30
Differentiation
Low grade20.30.0512.40.08
Intermediate grade2.370.462.780.37
High grade1.00
Number of nodules> 1070.99> 1070.99
Size of the largest nodule1.290.051.330.009
Microvascular invasion3.320.191.880.44
OKUDA1.540.512.920.09
CLIP1.260.602.390.03